News Channels

26 Apr 2022 Update on Regulatory Submission for Aducanumab in the European Union
26 Apr 2022 Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
24 Apr 2022 Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
24 Apr 2022 New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
21 Apr 2022 Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
21 Apr 2022 Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
20 Apr 2022 VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
20 Apr 2022 Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
20 Apr 2022 Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
20 Apr 2022 Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
20 Apr 2022 Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC008
20 Apr 2022 AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
20 Apr 2022 Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
20 Apr 2022 SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
20 Apr 2022 Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
20 Apr 2022 SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
20 Apr 2022 BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
20 Apr 2022 Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
19 Apr 2022 Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
19 Apr 2022 Amgen announces positive top-line results from phase 3 study of ABP 654, biosimilar candidate to Stelara (ustekinumab)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up